Jefferies Group reaffirmed their buy rating on shares of Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) in a research report sent to investors on Monday. They currently have a $3.00 target price on the biopharmaceutical company’s stock.

MRNS has been the topic of a number of other reports. Oppenheimer Holdings Inc. cut Marinus Pharmaceuticals from an outperform rating to a market perform rating in a research note on Tuesday, June 14th. Zacks Investment Research upgraded Marinus Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, August 19th. Goldman Sachs Group Inc. cut Marinus Pharmaceuticals from a buy rating to a neutral rating in a research note on Tuesday, June 14th. Stifel Nicolaus restated a hold rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 28th. Finally, Royal Bank Of Canada cut Marinus Pharmaceuticals from an outperform rating to a sector perform rating and decreased their price target for the stock from $14.00 to $2.00 in a research note on Tuesday, June 14th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Marinus Pharmaceuticals presently has a consensus rating of Hold and a consensus target price of $7.90.

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Marinus Pharmaceuticals (NASDAQ:MRNS) opened at 1.57 on Monday. The stock’s market capitalization is $30.63 million. The company’s 50-day moving average price is $1.74 and its 200 day moving average price is $3.22. Marinus Pharmaceuticals has a 52 week low of $1.19 and a 52 week high of $10.24.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.08. Equities research analysts expect that Marinus Pharmaceuticals will post ($1.65) EPS for the current fiscal year.

In other news, major shareholder Vii Lp Canaan sold 20,380 shares of the stock in a transaction on Tuesday, July 26th. The stock was sold at an average price of $1.81, for a total value of $36,887.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.00% of the stock is owned by insiders.

A hedge fund recently raised its stake in Marinus Pharmaceuticals stock. Vanguard Group Inc. increased its stake in shares of Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) by 2.8% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 283,380 shares of the biopharmaceutical company’s stock after buying an additional 7,618 shares during the period. Vanguard Group Inc. owned 1.45% of Marinus Pharmaceuticals worth $360,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 45.64% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

5 Day Chart for NASDAQ:MRNS

Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.